Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 03

249P - Improving quality of life and symptom burden with opioids and adjuncts in lung cancer (IQSOL study)

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Supportive and Palliative Care

Tumour Site

Small Cell Lung Cancer;  Non-Small Cell Lung Cancer

Presenters

Naren Gokulanathan

Citation

Annals of Oncology (2022) 33 (suppl_9): S1530-S1532. 10.1016/annonc/annonc1129

Authors

N. Gokulanathan1, G. Karunanithi1, M. Muthukarthikeyan2

Author affiliations

  • 1 Radiation Oncology, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN
  • 2 Radiation Oncology Department, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 249P

Background

Pain and cough are the two commonest presenting symptoms in lung cancer, with an incidence of 51% and 65%, causing significant distress to the patient and caretakers. This study highlights the impact of opioid analgesics and adjuncts in relieving symptom burden and eventual improvement in cough specific quality of life.

Methods

This retrospective study comprises 107 lung cancer patients under JIPMER palliative registry from Jan-2019 till Oct-2021. Survival and QOL data were collected from patients and caretakers via telephone. Clinical data was collected from medical records. Symptom burden was assessed with the Visual Analog Scale and Cough VAS scale, while cough-QOL was assessed with the MCLCS (Manchester Cough in Lung Cancer Scale) at the time of clinical follow up.

Results

Comparing the data of patients who had received opioid analgesics without adjuncts (n=25), the patients who had received opioid analgesics (n=82) along with adjuncts (Gabapentin 600 mg/day and Amitriptyline 25 mg/day), had a better cough relief (19% v 45%) and improved cough QOL (20% v 32%). G+A subgroup showed a 20.7% reduction of mean baseline morphine dose at subsequent visits. Gabapentin subgroup had a 10% reduction of mean baseline dose. Reduction in mean cough VAS in opioids only group Vs Opioid + Adjunct group is 17.3% Vs 40.4%. Gabapentin subgroup has 39% reduction while G+A subgroup has 40.6% reduction in the mean cough VAS. Reduction in Mean MCLCS score in opioids only group Vs Opioid + Adjunct group is 17.8% Vs 35.5%. Per the MCLCS, in the gabapentin subgroup has 36.6% reduction while G+A subgroup has 27.3% reduction.

Conclusions

Inferring from the above data, patients with adjuncts have better mean cough VAS and QOL according to the MCLCS questionnaire, in addition to reduction in overall pain, when compared to patients who received only opioids for their pain. In addition to primary treatment with radiotherapy and chemotherapy, palliative care forms a core component in management of lung cancers and their symptom burden. Antitussive properties of opioids appear to be accentuated when given along with adjuncts. The efficacy of adjuncts, though well studied in other chronic cough conditions, need to be evaluated further in thoracic malignancies, especially lung cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.